177 related articles for article (PubMed ID: 7805018)
41. Adenoviral-mediated gene therapy with Ad5CMVp53 and Ad5CMVp21 in combination with standard therapies in human breast cancer cell lines.
Parker LP; Wolf JK; Price JE
Ann Clin Lab Sci; 2000 Oct; 30(4):395-405. PubMed ID: 11045764
[TBL] [Abstract][Full Text] [Related]
42. Adenoviral-mediated p53 tumor suppressor gene therapy of human ovarian carcinoma.
Mujoo K; Maneval DC; Anderson SC; Gutterman JU
Oncogene; 1996 Apr; 12(8):1617-23. PubMed ID: 8622881
[TBL] [Abstract][Full Text] [Related]
43. Combination therapy of malignant glioma cells with 2-5A-antisense telomerase RNA and recombinant adenovirus p53.
Komata T; Kondo Y; Koga S; Ko SC; Chung LW; Kondo S
Gene Ther; 2000 Dec; 7(24):2071-9. PubMed ID: 11223987
[TBL] [Abstract][Full Text] [Related]
44. Combination E2F-1 and p53 gene transfer does not enhance growth inhibition in human squamous cell carcinoma of the head and neck.
Frank DK; Liu TJ; Frederick MJ; Clayman GL
Clin Cancer Res; 1998 Sep; 4(9):2265-72. PubMed ID: 9748148
[TBL] [Abstract][Full Text] [Related]
45. Combination of mutated herpes simplex virus type 1 (G207 virus) with radiation for the treatment of squamous cell carcinoma of the head and neck.
Kim SH; Wong RJ; Kooby DA; Carew JF; Adusumilli PS; Patel SG; Shah JP; Fong Y
Eur J Cancer; 2005 Jan; 41(2):313-22. PubMed ID: 15661558
[TBL] [Abstract][Full Text] [Related]
46. The evaluation of adenoviral p53-mediated bystander effect in gene therapy of cancer.
Rizk NP; Chang MY; El Kouri C; Seth P; Kaiser LR; Albelda SM; Amin KM
Cancer Gene Ther; 1999; 6(4):291-301. PubMed ID: 10419047
[TBL] [Abstract][Full Text] [Related]
47. Adenoviral delivery of p53 gene suppresses expression of collagenase-3 (MMP-13) in squamous carcinoma cells.
Ala-aho R; Grénman R; Seth P; Kähäri VM
Oncogene; 2002 Feb; 21(8):1187-95. PubMed ID: 11850838
[TBL] [Abstract][Full Text] [Related]
48. Effect of human papillomavirus-16 infection on CD8+ T-cell recognition of a wild-type sequence p53264-272 peptide in patients with squamous cell carcinoma of the head and neck.
Sirianni N; Ha PK; Oelke M; Califano J; Gooding W; Westra W; Whiteside TL; Koch WM; Schneck JP; DeLeo A; Ferris RL
Clin Cancer Res; 2004 Oct; 10(20):6929-37. PubMed ID: 15501971
[TBL] [Abstract][Full Text] [Related]
49. [Gene therapy and molecular therapeutic for head and neck cancer].
Tanaka H
Gan To Kagaku Ryoho; 2005 Dec; 32(13):2046-51. PubMed ID: 16352927
[TBL] [Abstract][Full Text] [Related]
50. [Progress of gene therapy for esophageal cancer in Japan].
Matsubara H; Ochiai T
Gan To Kagaku Ryoho; 2003 Jul; 30(7):944-9. PubMed ID: 12894708
[TBL] [Abstract][Full Text] [Related]
51. Development and validation of sensitive assays to quantitate gene expression after p53 gene therapy and paclitaxel chemotherapy using in vivo dosing in tumor xenograft models.
Wen SF; Xie L; McDonald M; DiGiacomo R; Chang A; Gurnani M; Shi B; Liu S; Indelicato SR; Hutchins B; Nielsen LL
Cancer Gene Ther; 2000 Nov; 7(11):1469-80. PubMed ID: 11129289
[TBL] [Abstract][Full Text] [Related]
52. Head and neck cancer: response to p53-based therapeutics.
Nemunaitis J; Nemunaitis J
Head Neck; 2011 Jan; 33(1):131-4. PubMed ID: 20222046
[TBL] [Abstract][Full Text] [Related]
53. Gene therapy for head and neck cancer. Comparing the tumor suppressor gene p53 and a cell cycle regulator WAF1/CIP1 (p21).
Clayman GL; Liu TJ; Overholt SM; Mobley SR; Wang M; Janot F; Goepfert H
Arch Otolaryngol Head Neck Surg; 1996 May; 122(5):489-93. PubMed ID: 8615965
[TBL] [Abstract][Full Text] [Related]
54. Adenovirus-mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma.
Clayman GL; el-Naggar AK; Lippman SM; Henderson YC; Frederick M; Merritt JA; Zumstein LA; Timmons TM; Liu TJ; Ginsberg L; Roth JA; Hong WK; Bruso P; Goepfert H
J Clin Oncol; 1998 Jun; 16(6):2221-32. PubMed ID: 9626224
[TBL] [Abstract][Full Text] [Related]
55. Enhancement of Ad-p53 therapy with docetaxel in head and neck cancer.
Yoo GH; Piechocki MP; Oliver J; Lonardo F; Zumstein L; Lin HS; Kim H; Shibuya TY; Shehadeh N; Ensley JF
Laryngoscope; 2004 Nov; 114(11):1871-9. PubMed ID: 15510008
[TBL] [Abstract][Full Text] [Related]
56. Role of histone deacetylase inhibitor in adenovirus-mediated p53 gene therapy in esophageal cancer.
Hoshino I; Matsubara H; Akutsu Y; Nishimori T; Yoneyama Y; Murakami K; Sakata H; Matsushita K; Komatsu A; Brooks R; Ochiai T
Anticancer Res; 2008; 28(2A):665-71. PubMed ID: 18507005
[TBL] [Abstract][Full Text] [Related]
57. Controversial Chinese gene-therapy drug entering unfamiliar territory.
Jia H
Nat Rev Drug Discov; 2006 Apr; 5(4):269-70. PubMed ID: 16628829
[No Abstract] [Full Text] [Related]
58. Preclinical study of adenoviral p53 gene therapy for esophageal cancer.
Shimada H; Shimizu T; Ochiai T; Liu TL; Sashiyama H; Nakamura A; Matsubara H; Gunji Y; Kobayashi S; Tagawa M; Sakiyama S; Hiwasa T
Surg Today; 2001; 31(7):597-604. PubMed ID: 11495154
[TBL] [Abstract][Full Text] [Related]
59. In vitro growth suppression by adenoviral transduction of p21 and p16 in squamous cell carcinoma of the head and neck: a research model for combination gene therapy.
Mobley SR; Liu TJ; Hudson JM; Clayman GL
Arch Otolaryngol Head Neck Surg; 1998 Jan; 124(1):88-92. PubMed ID: 9440786
[TBL] [Abstract][Full Text] [Related]
60. A combined lymphokine-activated killer (LAK) cell immunotherapy and adenovirus-p53 gene therapy for head and neck squamous cell carcinoma.
Saito H; Ando S; Morishita N; Lee KM; Dator D; Dy D; Shigemura K; Adhim Z; Nibu K; Fujisawa M; Shirakawa T
Anticancer Res; 2014 Jul; 34(7):3365-70. PubMed ID: 24982341
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
